254 related articles for article (PubMed ID: 20068102)
1. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
Bauer JA; Chakravarthy AB; Rosenbluth JM; Mi D; Seeley EH; De Matos Granja-Ingram N; Olivares MG; Kelley MC; Mayer IA; Meszoely IM; Means-Powell JA; Johnson KN; Tsai CJ; Ayers GD; Sanders ME; Schneider RJ; Formenti SC; Caprioli RM; Pietenpol JA
Clin Cancer Res; 2010 Jan; 16(2):681-90. PubMed ID: 20068102
[TBL] [Abstract][Full Text] [Related]
2. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
O'Brien C; Cavet G; Pandita A; Hu X; Haydu L; Mohan S; Toy K; Rivers CS; Modrusan Z; Amler LC; Lackner MR
Cancer Res; 2008 Jul; 68(13):5380-9. PubMed ID: 18593940
[TBL] [Abstract][Full Text] [Related]
3. The determination of changes in the expression of genes for selected specific transcriptional factors in in vitro ductal breast cancer cells under the influence of paclitaxel.
Ziaja-Sołtys M; Rzymowska J
Cell Mol Biol Lett; 2011 Dec; 16(4):610-24. PubMed ID: 21909792
[TBL] [Abstract][Full Text] [Related]
4. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
5. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy.
Moulder S; Yan K; Huang F; Hess KR; Liedtke C; Lin F; Hatzis C; Hortobagyi GN; Symmans WF; Pusztai L
Mol Cancer Ther; 2010 May; 9(5):1120-7. PubMed ID: 20423993
[TBL] [Abstract][Full Text] [Related]
6. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Lee JK; Coutant C; Kim YC; Qi Y; Theodorescu D; Symmans WF; Baggerly K; Rouzier R; Pusztai L
Clin Cancer Res; 2010 Jan; 16(2):711-8. PubMed ID: 20068086
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
Chakravarthy AB; Kelley MC; McLaren B; Truica CI; Billheimer D; Mayer IA; Grau AM; Johnson DH; Simpson JF; Beauchamp RD; Jones C; Pietenpol JA
Clin Cancer Res; 2006 Mar; 12(5):1570-6. PubMed ID: 16533783
[TBL] [Abstract][Full Text] [Related]
8. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
Rodrigues-Ferreira S; Nehlig A; Moindjie H; Monchecourt C; Seiler C; Marangoni E; Chateau-Joubert S; Dujaric ME; Servant N; Asselain B; de Cremoux P; Lacroix-Triki M; Arnedos M; Pierga JY; André F; Nahmias C
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23691-23697. PubMed ID: 31685623
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
11. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
12. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
13. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
14. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Horak CE; Pusztai L; Xing G; Trifan OC; Saura C; Tseng LM; Chan S; Welcher R; Liu D
Clin Cancer Res; 2013 Mar; 19(6):1587-95. PubMed ID: 23340299
[TBL] [Abstract][Full Text] [Related]
15. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.
Petrarca CR; Brunetto AT; Duval V; Brondani A; Carvalho GP; Garicochea B
Clin Breast Cancer; 2011 Apr; 11(2):129-34. PubMed ID: 21569999
[TBL] [Abstract][Full Text] [Related]
16. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Bedard PL; Singhal SK; Ignatiadis M; Bradbury I; Haibe-Kains B; Desmedt C; Loi S; Evans DB; Michiels S; Dixon JM; Miller WR; Piccart MJ; Sotiriou C
Endocr Relat Cancer; 2011 Dec; 18(6):721-30. PubMed ID: 21984694
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Park S; Shimizu C; Shimoyama T; Takeda M; Ando M; Kohno T; Katsumata N; Kang YK; Nishio K; Fujiwara Y
Breast Cancer Res Treat; 2006 Sep; 99(1):9-17. PubMed ID: 16752223
[TBL] [Abstract][Full Text] [Related]
18. Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.
Kraus JA; Beriwal S; Dabbs DJ; Ahrendt GM; McGuire KP; Johnson RR; Badve P; Puhalla SL; Bhargava R
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):334-9. PubMed ID: 22417856
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
